Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a correction disclosure extending the disclosure postponement period, specifying the contract end date, and updating the counterparty disclosure schedule to August 1, 2031, at the customer’s request regarding the contract manufacturing agreement originally disclosed on November 28, 2023.
📊 [Key Disclosure Details & Financial Figures]
- Original Filing & Submission Date: Single Sales and Supply Contract (Submitted on November 28, 2023)
- Reason for Correction: Extension of disclosure postponement period at the customer’s request
- Key Correction Items:
- Contract Period End Date: (Before) Unstated (-) → (After) August 1, 2031
- Disclosure Postponement Period: (Before) December 31, 2025 → (After) August 1, 2031
- Other Important Matters (Counterparty Disclosure Timeline): (Before) To be disclosed after December 31, 2025 → (After) To be disclosed after August 1, 2031
- Contract Overview (Based on Original Filing):
- Contract Title: Pharmaceutical Contract Manufacturing Agreement
- Contract Amount: KRW 588,781,733,375 (USD 451,277,484 / Confirmed contract amount, applied exchange rate KRW 1,304.70 per USD)
- Recent Annual Revenue: KRW 3,001,295,197,683 (Based on FY2022 consolidated financial statements)
- Contract Amount to Revenue Ratio: 19.62%
- Counterparty: Pharmaceutical company based in Asia
- Contract Period: August 1, 2019 – August 1, 2031
- Contract Date: November 28, 2023
- Other Important Investment Details:
- This contract reflects an increase in production volume from a previously signed agreement.
- The contract end date and contract amount are subject to change upon mutual agreement.
- Counterparty identity is slated for disclosure after August 1, 2031, due to business confidentiality.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Disclosure Timeline and Contract Updates Following Postponement Extension
This correction disclosure updates the confidentiality postponement period, contract end date, and counterparty disclosure timeline for the contract manufacturing deal with an Asian pharmaceutical company to August 1, 2031.
Monitoring the adjusted disclosure schedule and potential updates to contract amounts is essential for tracking the ongoing execution of this agreement.
Relevant developments can be verified upon the expiration of the extended postponement period (August 1, 2031) or through subsequent correction disclosures and periodic reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
